Loading...

Tau-Targeting Therapies May Transform Alzheimer's Treatment Despite Clinical Uncertainties

Published
26 Jan 25
Updated
01 May 25
AnalystConsensusTarget's Fair Value
US$15.67
68.4% undervalued intrinsic discount
10 Sep
US$4.95
Loading
1Y
-27.1%
7D
5.1%

Author's Valuation

US$15.6768.4% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Increased 18%

Shared on23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget has decreased profit margin from 19.3% to 17.3% and increased future PE multiple from 79.3x to 88.4x.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 16%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 0.77%

AnalystConsensusTarget has decreased revenue growth from -21.3% to -3.0%, increased profit margin from 15.8% to 19.6% and decreased future PE multiple from 88.1x to 77.5x.

Shared on11 Mar 25